The efficacy and safety of antiviral drugs of direct action in liver recipients with recurrence of chronic hepatitis C genotype 1 after transplantation
Aim. To study the efficacy and safety of the use of paritaprevir, ritonavir, ombitasvir and dasabuvir in combination or without ribavirin in liver recipients with recurrence of HCV 1 genotype after transplantation.Materials and methods. The study included 46 patients after orthotopic liver transplan...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov
2019-01-01
|
| Series: | Вестник трансплантологии и искусственных органов |
| Subjects: | |
| Online Access: | https://journal.transpl.ru/vtio/article/view/951 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849691239728807936 |
|---|---|
| author | О. M. Tsiroulnikova D. V. Umrik I. A. Miloserdov Е. Т. Egorova R. A. Latypov |
| author_facet | О. M. Tsiroulnikova D. V. Umrik I. A. Miloserdov Е. Т. Egorova R. A. Latypov |
| author_sort | О. M. Tsiroulnikova |
| collection | DOAJ |
| description | Aim. To study the efficacy and safety of the use of paritaprevir, ritonavir, ombitasvir and dasabuvir in combination or without ribavirin in liver recipients with recurrence of HCV 1 genotype after transplantation.Materials and methods. The study included 46 patients after orthotopic liver transplantation with recurrence of HCV 1 genotype. 37 patients completed a 24-week course of antiviral therapy, including paritaprevir, ritonavir, ombitasvir and dasabuvir in combination or without ribavirin. The effectiveness of the therapy was calculated as the proportion of patients who achieved aviremia 12 weeks after the end of the course of treatment. The safety of therapy was assessed by the number of adverse events that occurred during the course of antiviral therapy.Results. A sustained virologic response at 12 weeks after the end of the course of antiviral therapy, including paritaprevir, ritonavir, ombitasvir and dasabuvir, reached 100% of the recipients of the liver. Reduction in the intensity of cytolytic and cholestatic syndromes was noted at week 4 of therapy. Adverse events were recorded in 56.7% of the subjects, mostly they were not severe and were stopped on their own. Acute cellular rejection of the transplant developed in 1 patient (2.7%). There have been no cases of irreversible liver transplant dysfunction or death of the recipient.The conclusion. The use of paritaprevir, ritonavir, ombitasvir and dasabuvir is safe and effective in the treatment of relapse of HCV infection of 1 genotype after liver transplantation. |
| format | Article |
| id | doaj-art-ff05cd7fc15d4b8da2d87c11cbc430cf |
| institution | DOAJ |
| issn | 1995-1191 |
| language | Russian |
| publishDate | 2019-01-01 |
| publisher | Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov |
| record_format | Article |
| series | Вестник трансплантологии и искусственных органов |
| spelling | doaj-art-ff05cd7fc15d4b8da2d87c11cbc430cf2025-08-20T03:21:06ZrusFederal Research Center of Transplantology and Artificial Organs named after V.I.ShumakovВестник трансплантологии и искусственных органов1995-11912019-01-01204616810.15825/1995-1191-2018-4-61-68739The efficacy and safety of antiviral drugs of direct action in liver recipients with recurrence of chronic hepatitis C genotype 1 after transplantationО. M. Tsiroulnikova0D. V. Umrik1I. A. Miloserdov2Е. Т. Egorova3R. A. Latypov4V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University)V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University)V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationAim. To study the efficacy and safety of the use of paritaprevir, ritonavir, ombitasvir and dasabuvir in combination or without ribavirin in liver recipients with recurrence of HCV 1 genotype after transplantation.Materials and methods. The study included 46 patients after orthotopic liver transplantation with recurrence of HCV 1 genotype. 37 patients completed a 24-week course of antiviral therapy, including paritaprevir, ritonavir, ombitasvir and dasabuvir in combination or without ribavirin. The effectiveness of the therapy was calculated as the proportion of patients who achieved aviremia 12 weeks after the end of the course of treatment. The safety of therapy was assessed by the number of adverse events that occurred during the course of antiviral therapy.Results. A sustained virologic response at 12 weeks after the end of the course of antiviral therapy, including paritaprevir, ritonavir, ombitasvir and dasabuvir, reached 100% of the recipients of the liver. Reduction in the intensity of cytolytic and cholestatic syndromes was noted at week 4 of therapy. Adverse events were recorded in 56.7% of the subjects, mostly they were not severe and were stopped on their own. Acute cellular rejection of the transplant developed in 1 patient (2.7%). There have been no cases of irreversible liver transplant dysfunction or death of the recipient.The conclusion. The use of paritaprevir, ritonavir, ombitasvir and dasabuvir is safe and effective in the treatment of relapse of HCV infection of 1 genotype after liver transplantation.https://journal.transpl.ru/vtio/article/view/951chronic hepatitis crelapseliver transplantationdirect antiviral action3dtherapysustained virologic response |
| spellingShingle | О. M. Tsiroulnikova D. V. Umrik I. A. Miloserdov Е. Т. Egorova R. A. Latypov The efficacy and safety of antiviral drugs of direct action in liver recipients with recurrence of chronic hepatitis C genotype 1 after transplantation Вестник трансплантологии и искусственных органов chronic hepatitis c relapse liver transplantation direct antiviral action 3dtherapy sustained virologic response |
| title | The efficacy and safety of antiviral drugs of direct action in liver recipients with recurrence of chronic hepatitis C genotype 1 after transplantation |
| title_full | The efficacy and safety of antiviral drugs of direct action in liver recipients with recurrence of chronic hepatitis C genotype 1 after transplantation |
| title_fullStr | The efficacy and safety of antiviral drugs of direct action in liver recipients with recurrence of chronic hepatitis C genotype 1 after transplantation |
| title_full_unstemmed | The efficacy and safety of antiviral drugs of direct action in liver recipients with recurrence of chronic hepatitis C genotype 1 after transplantation |
| title_short | The efficacy and safety of antiviral drugs of direct action in liver recipients with recurrence of chronic hepatitis C genotype 1 after transplantation |
| title_sort | efficacy and safety of antiviral drugs of direct action in liver recipients with recurrence of chronic hepatitis c genotype 1 after transplantation |
| topic | chronic hepatitis c relapse liver transplantation direct antiviral action 3dtherapy sustained virologic response |
| url | https://journal.transpl.ru/vtio/article/view/951 |
| work_keys_str_mv | AT omtsiroulnikova theefficacyandsafetyofantiviraldrugsofdirectactioninliverrecipientswithrecurrenceofchronichepatitiscgenotype1aftertransplantation AT dvumrik theefficacyandsafetyofantiviraldrugsofdirectactioninliverrecipientswithrecurrenceofchronichepatitiscgenotype1aftertransplantation AT iamiloserdov theefficacyandsafetyofantiviraldrugsofdirectactioninliverrecipientswithrecurrenceofchronichepatitiscgenotype1aftertransplantation AT etegorova theefficacyandsafetyofantiviraldrugsofdirectactioninliverrecipientswithrecurrenceofchronichepatitiscgenotype1aftertransplantation AT ralatypov theefficacyandsafetyofantiviraldrugsofdirectactioninliverrecipientswithrecurrenceofchronichepatitiscgenotype1aftertransplantation AT omtsiroulnikova efficacyandsafetyofantiviraldrugsofdirectactioninliverrecipientswithrecurrenceofchronichepatitiscgenotype1aftertransplantation AT dvumrik efficacyandsafetyofantiviraldrugsofdirectactioninliverrecipientswithrecurrenceofchronichepatitiscgenotype1aftertransplantation AT iamiloserdov efficacyandsafetyofantiviraldrugsofdirectactioninliverrecipientswithrecurrenceofchronichepatitiscgenotype1aftertransplantation AT etegorova efficacyandsafetyofantiviraldrugsofdirectactioninliverrecipientswithrecurrenceofchronichepatitiscgenotype1aftertransplantation AT ralatypov efficacyandsafetyofantiviraldrugsofdirectactioninliverrecipientswithrecurrenceofchronichepatitiscgenotype1aftertransplantation |